Iodine-131 metaiodobenzylguanidine treatment for metastic carcinoid: Results in 98 patients

Shawn D. Safford, R. Edward Coleman, Jon P. Gockerman, Joseph Moore, Jerome Feldman, Mark W. Onaitis, Douglas Tyler, John A. Olson

Research output: Contribution to journalArticle

77 Citations (Scopus)

Abstract

BACKGROUND. Iodine-131 metaiodobenzylguanidine (131I-MIBG) is useful for imaging carcinoid tumors and recently has been applied to the palliative treatment of metastatic carcinoid in small studies. The authors now report their results on the therapeutic utility of high-dose 131I-MIBG treatment in a large group of patients with metastatic carcinoid tumors. METHODS. The authors performed a retrospective review of 98 patients with metastatic carcinoid who were treated at their institution with 131I-MIBG over a 15-year period. Endpoints examined included the World Health Organization criteria for treatment response: symptoms, hormone (5-hydroxyindoleacetic acid [5-HIAA]) production, and clinical tumor response. RESULTS. Patients received a median dose of 401 ± 202 millicuries (mCi) 131I-MIBG. The median survival after treatment was 2.3 years. Patients who experienced a symptomatic response had improved survival (5.76 years vs. 2.09 years; P < 0.01). For the 56 patients who had 5-HIAA levels monitored, the mean urine 5-HIAA levels decreased significantly after 131I-MIBG treatment (126 ± 122 ng/mL vs. 91 ± 125 ng/mL; P < 0.01); however, the patients with reduced 5-HIAA levels did not experience improved survival (4.11 years vs. 3.42 years; P = 0.2). Patients who received an initial 131I-MIBG dose > 400 mCi lived longer than patients who received < 400 mCi (4.69 years vs. 1.86 years; P = 0.05). Radiographic tumor response did not predict survival. Toxicity included pancytopenia, thrombocytopenia, nausea, and emesis. CONCLUSIONS. The current data support 131I-MIBG treatment in select patients with metastatic carcinoid who progress despite optimal medical management. Improved survival was predicted best by symptomatic response to 131I-MIBG treatment, but not by hormone or radiographic response.

Original languageEnglish (US)
Pages (from-to)1987-1993
Number of pages7
JournalCancer
Volume101
Issue number9
DOIs
StatePublished - Nov 1 2004
Externally publishedYes

Fingerprint

3-Iodobenzylguanidine
Carcinoid Tumor
Iodine
Survival
Therapeutics
Hormones
Pancytopenia
Hydroxyindoleacetic Acid
Palliative Care
Thrombocytopenia
Nausea
Vomiting
Neoplasms

Keywords

  • Carcinoid
  • Endocrine tumor
  • Metaiodobenzylguanidine
  • Palliative treatment

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Safford, S. D., Coleman, R. E., Gockerman, J. P., Moore, J., Feldman, J., Onaitis, M. W., ... Olson, J. A. (2004). Iodine-131 metaiodobenzylguanidine treatment for metastic carcinoid: Results in 98 patients. Cancer, 101(9), 1987-1993. https://doi.org/10.1002/cncr.20592

Iodine-131 metaiodobenzylguanidine treatment for metastic carcinoid : Results in 98 patients. / Safford, Shawn D.; Coleman, R. Edward; Gockerman, Jon P.; Moore, Joseph; Feldman, Jerome; Onaitis, Mark W.; Tyler, Douglas; Olson, John A.

In: Cancer, Vol. 101, No. 9, 01.11.2004, p. 1987-1993.

Research output: Contribution to journalArticle

Safford, SD, Coleman, RE, Gockerman, JP, Moore, J, Feldman, J, Onaitis, MW, Tyler, D & Olson, JA 2004, 'Iodine-131 metaiodobenzylguanidine treatment for metastic carcinoid: Results in 98 patients', Cancer, vol. 101, no. 9, pp. 1987-1993. https://doi.org/10.1002/cncr.20592
Safford SD, Coleman RE, Gockerman JP, Moore J, Feldman J, Onaitis MW et al. Iodine-131 metaiodobenzylguanidine treatment for metastic carcinoid: Results in 98 patients. Cancer. 2004 Nov 1;101(9):1987-1993. https://doi.org/10.1002/cncr.20592
Safford, Shawn D. ; Coleman, R. Edward ; Gockerman, Jon P. ; Moore, Joseph ; Feldman, Jerome ; Onaitis, Mark W. ; Tyler, Douglas ; Olson, John A. / Iodine-131 metaiodobenzylguanidine treatment for metastic carcinoid : Results in 98 patients. In: Cancer. 2004 ; Vol. 101, No. 9. pp. 1987-1993.
@article{479e463543404dbc8d39d7eee110d288,
title = "Iodine-131 metaiodobenzylguanidine treatment for metastic carcinoid: Results in 98 patients",
abstract = "BACKGROUND. Iodine-131 metaiodobenzylguanidine (131I-MIBG) is useful for imaging carcinoid tumors and recently has been applied to the palliative treatment of metastatic carcinoid in small studies. The authors now report their results on the therapeutic utility of high-dose 131I-MIBG treatment in a large group of patients with metastatic carcinoid tumors. METHODS. The authors performed a retrospective review of 98 patients with metastatic carcinoid who were treated at their institution with 131I-MIBG over a 15-year period. Endpoints examined included the World Health Organization criteria for treatment response: symptoms, hormone (5-hydroxyindoleacetic acid [5-HIAA]) production, and clinical tumor response. RESULTS. Patients received a median dose of 401 ± 202 millicuries (mCi) 131I-MIBG. The median survival after treatment was 2.3 years. Patients who experienced a symptomatic response had improved survival (5.76 years vs. 2.09 years; P < 0.01). For the 56 patients who had 5-HIAA levels monitored, the mean urine 5-HIAA levels decreased significantly after 131I-MIBG treatment (126 ± 122 ng/mL vs. 91 ± 125 ng/mL; P < 0.01); however, the patients with reduced 5-HIAA levels did not experience improved survival (4.11 years vs. 3.42 years; P = 0.2). Patients who received an initial 131I-MIBG dose > 400 mCi lived longer than patients who received < 400 mCi (4.69 years vs. 1.86 years; P = 0.05). Radiographic tumor response did not predict survival. Toxicity included pancytopenia, thrombocytopenia, nausea, and emesis. CONCLUSIONS. The current data support 131I-MIBG treatment in select patients with metastatic carcinoid who progress despite optimal medical management. Improved survival was predicted best by symptomatic response to 131I-MIBG treatment, but not by hormone or radiographic response.",
keywords = "Carcinoid, Endocrine tumor, Metaiodobenzylguanidine, Palliative treatment",
author = "Safford, {Shawn D.} and Coleman, {R. Edward} and Gockerman, {Jon P.} and Joseph Moore and Jerome Feldman and Onaitis, {Mark W.} and Douglas Tyler and Olson, {John A.}",
year = "2004",
month = "11",
day = "1",
doi = "10.1002/cncr.20592",
language = "English (US)",
volume = "101",
pages = "1987--1993",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "9",

}

TY - JOUR

T1 - Iodine-131 metaiodobenzylguanidine treatment for metastic carcinoid

T2 - Results in 98 patients

AU - Safford, Shawn D.

AU - Coleman, R. Edward

AU - Gockerman, Jon P.

AU - Moore, Joseph

AU - Feldman, Jerome

AU - Onaitis, Mark W.

AU - Tyler, Douglas

AU - Olson, John A.

PY - 2004/11/1

Y1 - 2004/11/1

N2 - BACKGROUND. Iodine-131 metaiodobenzylguanidine (131I-MIBG) is useful for imaging carcinoid tumors and recently has been applied to the palliative treatment of metastatic carcinoid in small studies. The authors now report their results on the therapeutic utility of high-dose 131I-MIBG treatment in a large group of patients with metastatic carcinoid tumors. METHODS. The authors performed a retrospective review of 98 patients with metastatic carcinoid who were treated at their institution with 131I-MIBG over a 15-year period. Endpoints examined included the World Health Organization criteria for treatment response: symptoms, hormone (5-hydroxyindoleacetic acid [5-HIAA]) production, and clinical tumor response. RESULTS. Patients received a median dose of 401 ± 202 millicuries (mCi) 131I-MIBG. The median survival after treatment was 2.3 years. Patients who experienced a symptomatic response had improved survival (5.76 years vs. 2.09 years; P < 0.01). For the 56 patients who had 5-HIAA levels monitored, the mean urine 5-HIAA levels decreased significantly after 131I-MIBG treatment (126 ± 122 ng/mL vs. 91 ± 125 ng/mL; P < 0.01); however, the patients with reduced 5-HIAA levels did not experience improved survival (4.11 years vs. 3.42 years; P = 0.2). Patients who received an initial 131I-MIBG dose > 400 mCi lived longer than patients who received < 400 mCi (4.69 years vs. 1.86 years; P = 0.05). Radiographic tumor response did not predict survival. Toxicity included pancytopenia, thrombocytopenia, nausea, and emesis. CONCLUSIONS. The current data support 131I-MIBG treatment in select patients with metastatic carcinoid who progress despite optimal medical management. Improved survival was predicted best by symptomatic response to 131I-MIBG treatment, but not by hormone or radiographic response.

AB - BACKGROUND. Iodine-131 metaiodobenzylguanidine (131I-MIBG) is useful for imaging carcinoid tumors and recently has been applied to the palliative treatment of metastatic carcinoid in small studies. The authors now report their results on the therapeutic utility of high-dose 131I-MIBG treatment in a large group of patients with metastatic carcinoid tumors. METHODS. The authors performed a retrospective review of 98 patients with metastatic carcinoid who were treated at their institution with 131I-MIBG over a 15-year period. Endpoints examined included the World Health Organization criteria for treatment response: symptoms, hormone (5-hydroxyindoleacetic acid [5-HIAA]) production, and clinical tumor response. RESULTS. Patients received a median dose of 401 ± 202 millicuries (mCi) 131I-MIBG. The median survival after treatment was 2.3 years. Patients who experienced a symptomatic response had improved survival (5.76 years vs. 2.09 years; P < 0.01). For the 56 patients who had 5-HIAA levels monitored, the mean urine 5-HIAA levels decreased significantly after 131I-MIBG treatment (126 ± 122 ng/mL vs. 91 ± 125 ng/mL; P < 0.01); however, the patients with reduced 5-HIAA levels did not experience improved survival (4.11 years vs. 3.42 years; P = 0.2). Patients who received an initial 131I-MIBG dose > 400 mCi lived longer than patients who received < 400 mCi (4.69 years vs. 1.86 years; P = 0.05). Radiographic tumor response did not predict survival. Toxicity included pancytopenia, thrombocytopenia, nausea, and emesis. CONCLUSIONS. The current data support 131I-MIBG treatment in select patients with metastatic carcinoid who progress despite optimal medical management. Improved survival was predicted best by symptomatic response to 131I-MIBG treatment, but not by hormone or radiographic response.

KW - Carcinoid

KW - Endocrine tumor

KW - Metaiodobenzylguanidine

KW - Palliative treatment

UR - http://www.scopus.com/inward/record.url?scp=7044237270&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=7044237270&partnerID=8YFLogxK

U2 - 10.1002/cncr.20592

DO - 10.1002/cncr.20592

M3 - Article

C2 - 15455358

AN - SCOPUS:7044237270

VL - 101

SP - 1987

EP - 1993

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 9

ER -